Skip to main content

Day: April 28, 2021

Marked return to growth – Q1 turnover: €593.8 million

Marked return to growth Q1 turnover: €593.8 millionin € million Q1 2021 Q1 2020 Change  France 250.5 271.9 -7.9%International 343.3 304.6 +12.7%       Total  593.8  576.5 +3.0%The SYNERGIE Group has begun 2021 with a marked return to growth, posting consolidated turnover on a like for like basis of €593.8 million (+3% compared with 2020). This performance was achieved thanks to the strategy implemented in France and in all the countries in which the Group operates, enabling it to conquer new markets in high-growth sectors (logistics, call centres, healthcare, agri-food, environment, digital and activities related to the transformation of cities). During the quarter, activity was again boosted by International, which strengthened its positions in both Northern Europe (+5%) and Southern Europe (+21.2%), where Italy played...

Continue reading

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de Charcot-Marie-Tooth de type 1A (CMT1A)

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de Charcot-Marie-Tooth de type 1A (CMT1A) Les nouveaux résultats suggèrent un bon profil de sécurité et une efficacité durable de PXT3003, évaluée sur l’échelle ONLS (Overall Neuropathy Limitation Scale), après une durée totale de 4 ans et demi d‘essai clinique Une conférence téléphonique et un webinar se tiendront demain jeudi 29 avril à 14h00 CET (8h00 ET) PARIS, France, le 28 avril 2021 à 18h00 (CET) – Pharnext SA (FR0011191287 – ALPHA) (« La Société »), société biopharmaceutique à un stade clinique avancé, pionnière d’une nouvelle approche de développement de combinaisons de médicaments innovantes basée sur les Big Data génomiques et l’intelligence...

Continue reading

Communiqué: Orange prices its 500 million euro, undated, 8-year non-call, deeply subordinated fixed to reset rate notes

Press releaseParis, 28 April 2021 NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA Orange prices its 500 million euro, undated, 8-year non-call, deeply subordinated fixed to reset rate notes Orange S.A. (the Company) successfully priced its issuance of €500,000,000 undated 8 year non-call deeply subordinated fixed to reset rate notes with a fixed coupon of 1.375% until the first call date (the Notes). The Notes are scheduled to be admitted to trading on Euronext Paris. It is also expected that rating agencies assign the New Notes a rating of Baa3/BBB- (Moody’s/ S&P) and an equity content of 50%. The Company also launched a tender offer (the Tender Offer) to repurchase its:€1,000,000,000 Undated 7 Year Non-Call Deeply Subordinated Fixed to Reset Rate Notes with first call date on 1 October 2021 (of which €118,374,000 is...

Continue reading

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good safety profile and sustained efficacy of PXT3003 as measured with the Overall Neuropathy Limitation Scale (‘ONLS’), after 4.5 years of total trial time. A live conference call and webcast will be held tomorrow, Thursday April 29that 2:00 p.m. CET (8:00 a.m. ET) PARIS, France, April 28, 2021, 6:00 p.m. CET – Pharnext SA (FR0011191287 – ALPHA) (the ‘Company’), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY™ platform, today announces new results from an interim analysis of an ongoing open-label...

Continue reading

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good safety profile and sustained efficacy of PXT3003 as measured with the Overall Neuropathy Limitation Scale (‘ONLS’), after 4.5 years of total trial time. A live conference call and webcast will be held tomorrow, Thursday April 29that 2:00 p.m. CET (8:00 a.m. ET) PARIS, France, April 28, 2021, 6:00 p.m. CET – Pharnext SA (FR0011191287 – ALPHA) (the ‘Company’), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY™ platform, today announces new results from an interim analysis of an ongoing open-label...

Continue reading

Festi hf.: Afkoma á 1. ársfjórðungi 2021

Helstu niðurstöðurFramlegð af vöru- og þjónustusölu nam 5.144 millj. kr. samanborið við 4.304 millj. kr. á 1F 2020, sem samsvarar 19,5% hækkun milli ára. EBITDA nam 1.505 millj. kr. samanborið við 1.021 millj. kr. á 1F 2020, sem jafngildir 47,5% hækkun. Framlegð af vörusölu var 24,6% á 1F 2021 en framlegðin var 22,9% á sama fjórðungi árið áður. Kostnaður vegna COVID-19 var 37 millj. kr. á 1F 2021 en var 48 millj. kr. á sama fjórðungi árið áður. Eigið fé í lok 1F 2021 var 29.227 m.kr. og eiginfjárhlutfall 34,8% samanborið við 35,7% í lok árs 2020. Nettó vaxtaberandi skuldir án leiguskuldbindinga var 30.276 millj. kr. í lok 1F 2021 samanborið við 29.986 millj. kr. í lok 2020. EBITDA spá félagsins fyrir árið 2021 er hækkuð um 400 millj. kr. og er nú 7.900 – 8.300 millj. kr. Eggert Þór Kristófersson, forstjóri Festi: Niðurstaða...

Continue reading

UPM-Kymmene Corporation: Managers’ Transactions (Brunow)

UPM-Kymmene Corporation        Stock Exchange Release (Managers’ Transactions) 28 April 2021 at 18:00 EEST UPM-Kymmene Corporation: Managers’ Transactions (Brunow)  On 30 March 2021, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company’s Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members’ behalf, and the rest in cash. In accordance with this resolution, a total of 1,710 shares have been purchased to Berndt Brunow as follows:  Person subject to the notification requirementName: Brunow, BerndtPosition: Deputy Chair of the BoardIssuer: UPM-Kymmene CorporationLEI: 213800EC6PW5VU4J9U64 Notification type: INITIAL NOTIFICATION____________________________________________ Transaction...

Continue reading

UPM-Kymmene Corporation: Managers’ Transactions (Gustafsson) 

UPM-Kymmene Corporation        Stock Exchange Release (Managers’ Transactions)        28 April 2021 at 18:00 EEST UPM-Kymmene Corporation: Managers’ Transactions (Gustafsson)  On 30 March 2021, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company’s Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members’ behalf, and the rest in cash. In accordance with this resolution, a total of 1,405 shares have been purchased to Jari Gustafsson as follows: Person subject to the notification requirementName: Gustafsson, JariPosition: Member of the BoardIssuer: UPM-Kymmene CorporationLEI: 213800EC6PW5VU4J9U64 Notification type: INITIAL NOTIFICATION____________________________________________ Transaction...

Continue reading

DTE Strengthens Pledge to Net Zero Goal by Collaborating with Automakers to Optimize EV Charging

DETROIT, April 28, 2021 (GLOBE NEWSWIRE) — DTE Energy, Michigan’s largest energy company, is collaborating with Electric Vehicle (EV) manufacturers to optimize EV charging through the new DTE Smart Charge program. This program aims to help the company balance energy demand on the grid while moving closer to its environmental goal of achieving net zero carbon emissions by 2050. DTE Smart Charge is a Demand Response (DR) program that will monitor and study EV charging and peak usage events. The program is looking for 1,000 volunteer EV owners who have the potential to earn up to $100 in gift cards depending on their participation level. This initiative is open to all Michigan residents who have a qualifying EV and receive residential electric service from DTE Energy. DTE is among one of a few energy companies in the U.S. running...

Continue reading

ServisFirst Bank Announces New Hire to Tampa Bay Banking Team

Jason Costello Named Pinellas County Executive TAMPA, Fla., April 28, 2021 (GLOBE NEWSWIRE) — ServisFirst Bank, a subsidiary of ServisFirst Bancshares (NASDAQ:SFBS), recently announced the addition of Jason Costello to ServisFirst Bank Tampa as Pinellas County Executive. In this role, Costello will assist commercial clients with their banking needs in the Tampa Bay area as he oversees the growth of ServisFirst Bank to Pinellas county. “We are very pleased to have Jason join our commercial team,” stated Gwynn Davey, ServisFirst Bank Tampa Bay Region President. “His broad experience and well-known reputation in the community will help us to expand our presence in Pinellas County.” Jason Costello, Pinellas County ExecutiveWith over sixteen years of successful banking experience, Jason Costello joins ServisFirst Bank as an experienced...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.